Cystatin C and cardiac hypertrophy in primary hypertension

Blood Pressure

Volumn 19, Issue 1, 2010, Pages 20-25

  Prats, Merche ^a   Font, Ramon ^a   Bardaj, Alfredo ^a   Gutierrez, Cristina ^a   Lalana, Marta ^b   Vilanova, Angels ^b   Martinez Vea, Alberto ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Cardiac hypertrophy; Cystatin C; Essential hypertension; Kidney function

Indexed keywords

BIOLOGICAL MARKER; CYSTATIN C;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE MASS INDEX; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE STRUCTURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; CARDIOMEGALY; CREATININE; CYSTATIN C; ECHOCARDIOGRAPHY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; TRIGLYCERIDES;

EID: 77649108086     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037050903416386     Document Type: Article

References (36)

1. Laterza OF, Price CP, Scout MG. Cystatin C: An improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699-707.
2. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79-83.
3. Newman DJ, Takkar H, Edwards RG, Wlikie M, White T, Grubb AO, et al.. Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312-318.
4. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Taurina A, et al.. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-34.
5. Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC, et al.. Factors infl uencing serum cystatin c levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65: 1416-1421.
6. Köttgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008;51:385-394.
7. Jernberg T, Lindahal B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342-2348.
8. Shilipak MG, Katz R, Fried LF, Seliger S, Newman A, Siskovick DS, et al.. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45: 268-271.
9. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al.. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
10. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al.. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142: 497-505.
11. Shlipak MG, Wassel FCL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, et al.. Cystatin C and mortality risk in the elderly: The health, aging and body composition study. J Am Soc Nephrol. 2006;17:254-261.
12. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al.. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145: 237-246.
13. Stevens LA, Levey AS. Chronic kidney disease in the elderly - How to assess risk. N Engl J Med. 2005;352:2122-2124.
14. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, et al.. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003; 26:895-899.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
16. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behering Nephelometer II system. Scand J Clin Lab Invest. 1999; 59:1-8.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results from a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
18. Schiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H, et al.. Recommendations for quantifi cation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantifi cation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al.. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
20. Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlöf B, Aalto T, et al.. Impact of different partition values on the prevalence of left ventricular hypertrophy and concentric geometry in a large hypertensive population: The LIFE study. Hypertension. 2000;35:6-12.
21. Valero FA, Martinez-Vea A, Bardaji A, Gutierrez C, Garcia C, Richart C, et al.. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1999;10: 1020-1026.
22. Ix JH, Schipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incidenTheart failure among persons with coronary heart disease. Data from the Heart and Soul Study. Circulation. 2007;115:173-179.
23. Djoussé L, Kurth T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians' Health Study(PHS). Am Heart J. 2008;155:82-86.
24. Piñón P, Kaski SC. Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information? Rev Esp Cardiol. 2006; 59:247-258.
25. Bardaji A, Martinez Vea A. Chronic Kidney diasease and the heart. Linked pathologies. Rev Esp Cardiol. 2008;61(suppl 2): 41-51.
26. Mitsnefes M, Timbal T, Kartal J, Kathman T, Mishra J, Devarajan P. Serum cystatin C and left ventricular diastolic dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2006;21:1293-1298. (Pubitemid 44203456)
27. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: Data from the Heart and Soul Study. J Cardiac Fail. 2006;12:601-607.
28. Levin A, Thompson CR, Ethier J, Carlisle EJF, Tobe S, Mendelssohn D, et al.. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
29. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320-327.
30. Leoncini G, Ratto E, Viazzi F, Conti N, Falqui V, Parodi A, et al.. Global risk stratifi cation in primary hypertension: The role of the kidney. J Hypertens. 2008;26:427-432.
31. Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, et al.. Differences in kidney function and incident hypertension: The multi-ethnic study of atherosclerosis. Ann Intern Med. 2008;148:501-508.
32. Bertomeu V, Fácila L, González-Juanatey JR, Cea-Calvo L, Aznar J, Mazón P, et al.. Blood pressure control in hypertensive patients with left ventricular hypertrophy. The VIIDA Study. Rev Esp Cardiol. 2007;60:1257-1263.
33. Peralta CA, Whooley MA, Ix JH, Shlipak MG. Kidney function and systolic blood pressure. New insights from cystatin C: Data from the Heart and Soul Study. Am J Hypertens. 2006;19:939-946.
34. Ratto E, Leoncini G, Viazzi F, Bezzante GP, Falqui V, Parodi A, et al.. Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension. J Hypertens. 2008;26: 345-350.
35. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. C-reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertens Res. 2007;30:1177-1185.
36. Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, et al.. Left ventricular hypertrophy, subclinical atherosclerosis, and Inflammation. Hypertension. 2007;49: 1385-1391.